Skip to main content
Premium Trial:

Request an Annual Quote

Michael McGarrity

MDxHealth has appointed Michael McGarrity as its CEO and member of the firm's board of directors. Prior to MDxHealth, McGarrity served as CEO of Sterilis Medical. Previously, he was CEO of Nanosphere before it was acquired by Luminex in 2016. Prior to Nanosphere, McGarrity served in leadership roles at Stryker.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.